On Tuesday, MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) said it completed the current Good Laboratory Practice preclinical safety program for Ketamir-2, a novel oral ketamine analog.

The results confirm no adverse findings, clearing a critical milestone as the company progresses toward submitting its Investigational New Drug (IND) application by year-end 2024.

Also Read: MIRA Pharmaceuticals’ Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

The company says that by demonstrating Ketamir-2’s robust safety profile in comprehensive preclinical studies, MIRA has significantly de-risked this critical aspect of drug development.

This milestone positions the company for a smoother regulatory pathway, potentially increasing the likelihood of successful clinical outcomes.

Highlights of Preclinical Findings:

• Cardiovascular Safety in Dogs: No adverse effects were noted at therapeutic doses.
• CNS Assessment in Rats: No significant CNS changes were observed at therapeutic dose levels, confirming a favorable safety profile. Effects in high-dose groups were limited, transient, and non-disruptive.
• Respiratory Safety in Rats: No respiratory-related effects were noted across all tested doses.
• 14-Day Toxicology in Dogs: Ketamir-2 was well-tolerated at daily doses up to 200 mg/kg, with no observed adverse effects. This dose established the No Observed Adverse Effect Level (NOAEL).
• Ames Test: Ketamir-2 was confirmed to be non-mutagenic, further supporting its safety profile.

The Phase 1 trial, set to begin in the first quarter of 2025, is designed to gather critical insights into the safety, tolerability, pharmacokinetics, and pharmacodynamics of Ketamir-2 in healthy subjects.

The trial will include a robust battery of pain tests to evaluate the drug’s effects on neuropathic pain and psychosis.

These evaluations are expected to provide data by Q2 2025, helping to understand how Ketamir-2 affects pain in humans prior to initiating Phase 2a trials in patients.

Building on the Phase 1 findings, MIRA plans to initiate a Phase 2a proof-of-concept study in Q4 2025, focusing on patients with neuropathic pain. Proof-of-concept results are anticipated by year-end 2025.

Price Action: At last check on Tuesday, MIRA stock was down 1.63% to $1.21 during the premarket session.

Read Next

• Google Quantum AI’s New Willow Chip Can Do in Minutes That Supercomputers Would Take 10 Septillion Years

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

This article EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.